

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

Claim 1. (Currently Amended) A method for inhibiting the action of TNF- $\alpha$  for treating nerve disorders in a subject by administering a TNF- $\alpha$  inhibitor comprising administering to said subject a therapeutically effective dosage of said TNF- $\alpha$  inhibitor wherein said TNF- $\alpha$  inhibitor is CDP-571 (~~HUMICADE™~~), D2E7, or CDP-870.

Claim 2. (Original) The method of claim 1, wherein the subject is a vertebrate.

Claim 3. (Original) The method of claim 2, wherein the vertebrate is a mammal.

Claim 4. (Original) The method of claim 3, wherein the mammal is a human.

Claim 5. (Original) The method of claim 1, wherein said nerve disorder is a spinal disorder.

Claim 6. (Original) The method of claim 1, wherein said nerve disorder is nerve root injury.

Claim 7. (Original) The method of claim 1, wherein said nerve disorder is caused by herniated discs.

Claim 8. (Original) The method of claim 1, wherein said nerve disorder is sciatica.

Claim 9. (Original) The method of claim 1, wherein said nerve disorder involves pain.

Claim 10. (Original) The method of claim 1, wherein said nerve disorder is nucleus pulposus-induced nerve injury.

Claim 11. (Original) The method of claim 1, wherein said nerve disorder is spinal cord compression.

Claim 12. (Original) The method of claim 1, wherein said TNF- $\alpha$  inhibitor is administered systemically or locally.

Claim 13. (Original) The method of claim 1, wherein said TNF- $\alpha$  inhibitor is administered parenterally.

Claim 14. (Original) The method of claim 1, wherein said TNF- $\alpha$  inhibitor is administered intramuscularly, intravenously, subcutaneously, orally, or rectally.

Claim 15. (Original) The method of claim 14, wherein said TNF- $\alpha$  inhibitor is administered intravenously by injection or infusion.

Claim 16. (Original) The method of claim 15, wherein said TNF- $\alpha$  inhibitor is administered orally at a dosage of about 20 mg to about 1,500 mg.

Claim 17. (Canceled)

Claim 18. (Previously Presented) The method of claim 1, wherein the TNF- $\alpha$  inhibitor is CDP-870 and is administered in a dosage of about 1 mg/kg to about 50 mg/kg body weight of said subject.

Claims 19-29. (Canceled)

Claim 30. (Previously Presented) The method of claim 1, wherein the TNF- $\alpha$  inhibitor is D2E7 and is administered in a dosage of about 0.1 mg/kg to about 50 mg/kg body weight of said subject.

Claim 31. (Previously Presented) A method for inhibiting the action of TNF- $\alpha$  for treating nerve disorders in a subject by administering a TNF- $\alpha$  inhibitor comprising administering to said subject a therapeutically effective dosage of said TNF- $\alpha$  inhibitor wherein said TNF- $\alpha$  inhibitor is a lactoferrin, CT3, ITF-2357, PD-168787, CLX-1100, M-PGA, NCS-700; PMS-601, RDP-58, TNF-484A, PCM-4, CBP-1011, SR-31747, AGT-1, Solimastat, CH-3697, NR58-3.14.3, RIP-3, Sch-23863, or SH